ATE362364T1 - Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten - Google Patents

Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten

Info

Publication number
ATE362364T1
ATE362364T1 AT03710114T AT03710114T ATE362364T1 AT E362364 T1 ATE362364 T1 AT E362364T1 AT 03710114 T AT03710114 T AT 03710114T AT 03710114 T AT03710114 T AT 03710114T AT E362364 T1 ATE362364 T1 AT E362364T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
substituted azabicyclo
compounds
muscarine receptor
hexane derivatives
Prior art date
Application number
AT03710114T
Other languages
English (en)
Inventor
Anita Mehta
Arundutt Viswanatham Silamkoti
Jang Bahadur Gupta
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Application granted granted Critical
Publication of ATE362364T1 publication Critical patent/ATE362364T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03710114T 2003-04-10 2003-04-10 Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten ATE362364T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2003/001333 WO2004089363A1 (en) 2003-04-10 2003-04-10 Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
ATE362364T1 true ATE362364T1 (de) 2007-06-15

Family

ID=33156168

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03710114T ATE362364T1 (de) 2003-04-10 2003-04-10 Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten

Country Status (11)

Country Link
US (1) US7592359B2 (de)
EP (1) EP1615634B1 (de)
JP (1) JP2006514978A (de)
CN (1) CN100406009C (de)
AT (1) ATE362364T1 (de)
AU (1) AU2003214535B2 (de)
BR (1) BR0318242A (de)
CA (1) CA2521788A1 (de)
DE (1) DE60313898T2 (de)
EA (1) EA009059B1 (de)
WO (1) WO2004089363A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60230683D1 (de) 2002-07-08 2009-02-12 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
EP1618091A1 (de) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituierte azabicyclohexanderivate als antagonisten von muscarinrezeptoren
CN100436414C (zh) 2003-04-11 2008-11-26 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的氮杂双环衍生物
WO2006054162A1 (en) * 2004-11-19 2006-05-26 Ranbaxy Laboratories Limited Azabicyclic muscarinic receptor antagonists
WO2007007281A2 (en) * 2005-07-11 2007-01-18 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
EP1934184A1 (de) 2005-10-05 2008-06-25 Ranbaxy Laboratories, Ltd. 3 -azabicyclooctanderivate als antagonisten des muscarinrezeptors
US20100222393A1 (en) 2005-12-30 2010-09-02 Naresh Kumar Muscarinic receptor antagonists
US20090137623A1 (en) 2005-12-30 2009-05-28 Naresh Kumar Muscarinic receptor antagonists
WO2008029349A2 (en) * 2006-09-04 2008-03-13 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
WO2022034146A1 (en) 2020-08-13 2022-02-17 Boehringer Ingelheim International Gmbh Treatment of cognitive impairement associated with schizophrenia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (de) 1960-07-26
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
IE66202B1 (en) 1989-08-16 1995-12-13 Pfizer Azabicyclo quinolone carboxylic acids
GB8928042D0 (en) 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
US5281601A (en) * 1989-12-12 1994-01-25 Pfizer Inc. Muscarinic receptor antagonists
GB9202443D0 (en) 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
FI100051B (fi) 1992-02-18 1997-09-15 Favorit Oy Kompostori
JP3429338B2 (ja) 1992-07-27 2003-07-22 杏林製薬株式会社 新規なアリールグリシンアミド誘導体及びその製造法
JPH06135958A (ja) 1992-10-28 1994-05-17 Tanabe Seiyaku Co Ltd ベンゾシクロヘプテン誘導体及びその製法
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
KR19990008109A (ko) 1995-04-28 1999-01-25 나가사까 겐지로 1,4-이치환 피페리딘 유도체
CA2179574A1 (en) * 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
ATE205490T1 (de) * 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
AU2793197A (en) 1996-05-31 1998-01-05 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
PE92198A1 (es) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
RU2238936C2 (ru) * 1996-11-11 2004-10-27 Кристиан Р. НОЕ Энантиомерно чистые основные эфиры арил-циклоалкилгидроксикарбоновых кислот, способ их получения и применение в лекарственных средствах
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
US7232835B2 (en) * 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists

Also Published As

Publication number Publication date
EA200501594A1 (ru) 2006-08-25
CA2521788A1 (en) 2004-10-21
US7592359B2 (en) 2009-09-22
DE60313898T2 (de) 2008-01-17
EA009059B1 (ru) 2007-10-26
EP1615634B1 (de) 2007-05-16
DE60313898D1 (de) 2007-06-28
CN100406009C (zh) 2008-07-30
AU2003214535A8 (en) 2004-11-01
BR0318242A (pt) 2006-04-04
EP1615634A1 (de) 2006-01-18
JP2006514978A (ja) 2006-05-18
US20070287732A1 (en) 2007-12-13
AU2003214535B2 (en) 2009-09-03
CN1794984A (zh) 2006-06-28
AU2003214535A1 (en) 2004-11-01
WO2004089363A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
ZA200500951B (en) Azabicyclo derivatives as muscarinic receptor antagonists
HK1079787A1 (zh) 用作毒蕈碱受體拮抗劑的3，6-二取代的氮雜雙環[3．1．0]己烷衍生物
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
IL182317A0 (en) Cgrp receptor antagonists
EP1804919A4 (de) Cgrp-rezeptorantagonisten
WO2004091514A3 (en) Cgrp receptor antagonists
WO2006041830A3 (en) Cgrp receptor antagonists
WO2006035282A3 (en) Muscarinic receptor antagonists
EP1802372A4 (de) Cgrp-rezeptorantagonisten
ATE362364T1 (de) Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
DE60227576D1 (de) 3,6-DISUBSTITUIERTE AZABICYCLO i3.1.0 -HEXANDERIVATIVE ALS ANTAGONISTEN DES MUSCARINREZEPTORS
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
WO2006054162A8 (en) Azabicyclic muscarinic receptor antagonists
ATE386738T1 (de) Flavaxat-derivate als muscarin-rezeptor antagonisten
WO2004067510A8 (en) 3,6-disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2006018708A3 (en) Pyrrolidine derivatives as muscarinic receptor antagonists
EA200801591A1 (ru) Антагонисты мускаринового рецептора
WO2006032994A3 (en) Muscarinic receptor antagonists
WO2007007281A3 (en) Muscarinic receptor antagonists
ATE419246T1 (de) Als antagonisten des muscarinrezeptors geeignete xanthinderivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties